Citigroup Inc Kiniksa Pharmaceuticals, Ltd. Transaction History

Citigroup Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$17.63 - $21.74 $2.55 Million - $3.14 Million	144,662 Added 312.05%	191,020 $3.77 Million
Q4 2023 Feb 09, 2024	SELL	$14.37 - $19.07 $255,685 - $339,312	-17,793 Reduced 27.74%	46,358 $813,000
Q3 2023 Nov 09, 2023	BUY	$13.62 - $20.2 $215,536 - $319,665	15,825 Added 32.75%	64,151 $1.11 Million
Q2 2023 Aug 10, 2023	SELL	$10.44 - $16.48 $887,765 - $1.4 Million	-85,035 Reduced 63.76%	48,326 $680,000
Q1 2023 May 11, 2023	BUY	$10.7 - $15.79 $965,707 - $1.43 Million	90,253 Added 209.36%	133,361 $1.43 Million
Q4 2022 Feb 09, 2023	BUY	$11.42 - $17.05 $470,846 - $702,971	41,230 Added 2195.42%	43,108 $645,000
Q3 2022 Nov 10, 2022	SELL	$9.76 - $13.41 $26,966 - $37,051	-2,763 Reduced 59.53%	1,878 $24,000
Q2 2022 Aug 10, 2022	BUY	$7.6 - $11.41 $13,528 - $20,309	1,780 Added 62.22%	4,641 $45,000
Q1 2022 May 12, 2022	SELL	$9.3 - $12.37 $659,974 - $877,837	-70,965 Reduced 96.12%	2,861 $29,000
Q4 2021 Feb 10, 2022	BUY	$10.39 - $15.15 $152,275 - $222,038	14,656 Added 24.77%	73,826 $869,000
Q3 2021 Nov 10, 2021	BUY	$11.39 - $16.23 $673,946 - $960,329	59,170 New	59,170 $674,000

1.95M

Ticker KNSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,470,400
Market Cap $687M
Description
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.